LUXEMBOURG & KALAMAZOO, Mich. - (Business Wire) ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.
About ABL Patent Licensing Technologies Sàrl:
ABL owns US patents (US 6, 081,786 and US 6, 188,988) and their foreign equivalents and is currently in the business of licensing intellectual property to diagnostic manufacturers, therapeutic companies, and diagnostic service providers.
About Viralliance Inc.:
Viralliance Inc. (VI) is a Delaware corporation, which develops technologies to evaluate in vitro drug potency on patient’s derived viruses, to support drug development and to optimize patient drug regimens. Services are provided both directly for R&D purposes and during the different stages of drug development and indirectly through regulated clinical partners for the clinical management of HIV patients.
Chalom Sayada - Director
ABL PATENT LICENSING TECHNOLOGIES, SARL
Phone: +352-2638-8941
or
http://www.viralliance.com
Viralliance Inc.
